Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA) an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince Youn H Kim; Steven M Horwitz; Reinhard Dummer; Julia Scarisbrick; Pietro Quaglino; Pier Luigi Zinzani; Pascal Wolter; Jose A Sanches; Pablo L Ortiz-Romero; Oleg E Akilov; Larisa Geskin; Judith Trotman; Kerry Taylor; Stephane Dalle; Michael Weichenthal; Jan Walewski; David Fisher; Brigitte Dréno; Rudolf Stadler; Tatyana Feldman; Timothy MKuzel; Yinghui Wang; Maria Corinna Palanca-Wessels; Erin Zagadailov; William L Trepicchio; Wenwen Zhang; Hui-Min Lin; Yi Liu; Dirk Huebner; Meredith Little; Sean Whittaker; Madeleine Duvic

Lancet London v. 390, n. 10094, p. 555-566, 2017

London 2017

Acesso online. A biblioteca também possui exemplares impressos.